COL4A2 Antibody [K16J16] | Primary Antibodies

Application: Reactivity: Human, Mouse, Rat

Usage Information

Dilution
IHC1:500

Application
IHC

Reactivity
Human, Mouse, Rat

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
168 kDa

Datasheet & SDS

Biological Description

Specificity
COL4A2 Antibody [K16J16] detects endogenous levels of total COL4A2 protein.

Clone
K16J16

Synonym(s)
Collagen alpha-2(IV) chain, COL4A2

Background
COL4A2 encodes the collagen type IV alpha 2 chain, which pairs with COL4A1 to form the prototypic α1(IV)₂α2(IV) heterotrimer that constitutes a major structural scaffold of basement membranes in vascular, renal, neural, and many other tissues, where this network combines with laminins, nidogen, and heparan sulfate proteoglycans to generate the characteristic “chicken‑wire” basement membrane meshwork that controls tissue architecture, barrier function, and cell–matrix signaling. The protein contains a large triple‑helical collagenous domain with Gly‑X‑Y repeats that self‑associate into higher‑order protomers and networks, flanked by a non‑collagenous NC1 domain at the C‑terminus; proteolytic processing of this NC1 domain yields the fragment canstatin, which exerts anti‑angiogenic and anti‑tumor activity by binding αvβ3 and αvβ5 integrins on endothelial and tumor cells, inhibiting proliferation and migration, reducing mitochondrial membrane potential, and inducing apoptosis through Fas‑dependent caspase‑8 and caspase‑9 activation and engagement of intrinsic death pathways. COL4A2 within the vessel wall basement membrane restrains vascular smooth muscle cell proliferation and provides mechanical stability and signaling cues to endothelial and mural cells, and its expression is regulated by transforming growth factor‑β via canonical Smad3/Smad4 signaling, where TGFβ1 stimulation increases COL4A1/COL4A2 mRNA and protein levels in human vascular smooth muscle cells, and pharmacologic ALK5 inhibition or combined SMAD3/SMAD4 knockdown abolishes this induction, demonstrating that TGFβ–Smad3/4 complexes act as necessary regulators of type IV collagen production in the arterial wall. Genetic and epistasis analyses link the COL4A1/COL4A2 locus with coronary artery disease risk, with interaction between COL4A1/COL4A2 variants and SMAD3 risk alleles supporting a functional axis in which TGFβ–Smad3‑dependent upregulation of COL4A2 influences extracellular matrix composition, vascular remodeling, and atherosclerotic susceptibility. Mutations in COL4A2, often shared mechanistically with COL4A1, impair proper folding, secretion, and network assembly of the α1(IV)₂α2(IV) heterotrimer, producing widespread basement membrane defects associated with cerebrovascular phenotypes including intracerebral hemorrhage, porencephaly, leukoencephalopathy, small‑vessel disease, and ocular and renal manifestations, reflecting the ubiquitous requirement of COL4A2‑containing collagen IV networks for microvascular integrity and organ homeostasis. In the liver, COL4A2 expression increases in preneoplastic and hepatocellular carcinoma tissues relative to normal liver and correlates with shorter progression‑free survival, and bioinformatic and network analyses indicate that COL4A1/2 engage integrin α2β1 to activate a signaling cascade centered on the PI3K–Akt pathway with connections to Wnt and MAPK pathways and downstream control of cell cycle and cytoskeletal organization, supporting a role for COL4A2‑rich extracellular matrix as a pro‑tumorigenic niche in hepatocarcinogenesis. Within tissue‑specific extracellular matrices such as the periodontal ligament niche, COL4A2 contributes to the osteogenic differentiation capacity of resident stem cells, indicating that COL4A2‑containing basement membrane and pericellular matrices provide instructive cues that direct lineage commitment and bone regeneration in a context‑dependent manner.

Background

COL4A2 encodes the collagen type IV alpha 2 chain, which pairs with COL4A1 to form the prototypic α1(IV)₂α2(IV) heterotrimer that constitutes a major structural scaffold of basement membranes in vascular, renal, neural, and many other tissues, where this network combines with laminins, nidogen, and heparan sulfate proteoglycans to generate the characteristic “chicken‑wire” basement membrane meshwork that controls tissue architecture, barrier function, and cell–matrix signaling. The protein contains a large triple‑helical collagenous domain with Gly‑X‑Y repeats that self‑associate into higher‑order protomers and networks, flanked by a non‑collagenous NC1 domain at the C‑terminus; proteolytic processing of this NC1 domain yields the fragment canstatin, which exerts anti‑angiogenic and anti‑tumor activity by binding αvβ3 and αvβ5 integrins on endothelial and tumor cells, inhibiting proliferation and migration, reducing mitochondrial membrane potential, and inducing apoptosis through Fas‑dependent caspase‑8 and caspase‑9 activation and engagement of intrinsic death pathways. COL4A2 within the vessel wall basement membrane restrains vascular smooth muscle cell proliferation and provides mechanical stability and signaling cues to endothelial and mural cells, and its expression is regulated by transforming growth factor‑β via canonical Smad3/Smad4 signaling, where TGFβ1 stimulation increases COL4A1/COL4A2 mRNA and protein levels in human vascular smooth muscle cells, and pharmacologic ALK5 inhibition or combined SMAD3/SMAD4 knockdown abolishes this induction, demonstrating that TGFβ–Smad3/4 complexes act as necessary regulators of type IV collagen production in the arterial wall. Genetic and epistasis analyses link the COL4A1/COL4A2 locus with coronary artery disease risk, with interaction between COL4A1/COL4A2 variants and SMAD3 risk alleles supporting a functional axis in which TGFβ–Smad3‑dependent upregulation of COL4A2 influences extracellular matrix composition, vascular remodeling, and atherosclerotic susceptibility. Mutations in COL4A2, often shared mechanistically with COL4A1, impair proper folding, secretion, and network assembly of the α1(IV)₂α2(IV) heterotrimer, producing widespread basement membrane defects associated with cerebrovascular phenotypes including intracerebral hemorrhage, porencephaly, leukoencephalopathy, small‑vessel disease, and ocular and renal manifestations, reflecting the ubiquitous requirement of COL4A2‑containing collagen IV networks for microvascular integrity and organ homeostasis. In the liver, COL4A2 expression increases in preneoplastic and hepatocellular carcinoma tissues relative to normal liver and correlates with shorter progression‑free survival, and bioinformatic and network analyses indicate that COL4A1/2 engage integrin α2β1 to activate a signaling cascade centered on the PI3K–Akt pathway with connections to Wnt and MAPK pathways and downstream control of cell cycle and cytoskeletal organization, supporting a role for COL4A2‑rich extracellular matrix as a pro‑tumorigenic niche in hepatocarcinogenesis. Within tissue‑specific extracellular matrices such as the periodontal ligament niche, COL4A2 contributes to the osteogenic differentiation capacity of resident stem cells, indicating that COL4A2‑containing basement membrane and pericellular matrices provide instructive cues that direct lineage commitment and bone regeneration in a context‑dependent manner.

References
https://pubmed.ncbi.nlm.nih.gov/26310581/ https://pubmed.ncbi.nlm.nih.gov/22914737/

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%